Hydrocortone

Hydrocortone is an oral prescription medication whose active ingredient is hydrocortisone, a glucocorticoid corticosteroid. It is supplied in tablet form (strength not specified) and is marketed in the European Union. Hydrocortisone belongs to the anti‑inflammatory and immunosuppressant therapeutic class and works by binding to glucocorticoid receptors to modify gene expression. The drug is classified under ATC code H02AB02 and is available only by prescription in most EU member states.

Hydrocortone is prescribed for conditions that require glucocorticoid replacement or anti‑inflammatory therapy.

- Adrenal insufficiency, including primary and secondary forms, to replace deficient cortisol. - Congenital adrenal hyperplasia, to suppress excess androgen production. - Inflammatory and autoimmune disorders such as rheumatoid arthritis, systemic lupus erythematosus, and inflammatory bowel disease. - Severe allergic reactions or asthma exacerbations when oral corticosteroid therapy is indicated. - Certain dermatologic or ophthalmic conditions when systemic treatment is preferred. - Management of acute adrenal crisis to rapidly restore glucocorticoid levels.

Oral hydrocortisone may cause a range of adverse reactions, varying from mild and transient to potentially serious.

Common: - Increased appetite or weight gain. - Fluid retention leading to mild edema. - Elevated blood glucose levels, especially in patients with diabetes. - Mood changes such as irritability or mild insomnia. - Gastrointestinal discomfort, including nausea or dyspepsia. - Skin thinning or easy bruising. - Mild headache or dizziness.

Serious: - Severe hyperglycemia or new‑onset diabetes. - Hypertension or worsening of existing high blood pressure. - Osteoporosis or increased risk of fractures with long‑term use. - Suppression of the hypothalamic‑pituitary‑adrenal axis, risking adrenal crisis on abrupt discontinuation. - Opportunistic infections due to immunosuppression. - Psychiatric disturbances such as depression or psychosis.

Before initiating hydrocortone therapy, clinicians should evaluate several patient‑specific factors to minimize risks and ensure appropriate use.

- Assess for active infections, as glucocorticoids can worsen bacterial, viral, or fungal diseases. - Evaluate blood glucose and blood pressure, especially in patients with diabetes or hypertension. - Review history of osteoporosis, fractures, or chronic bone disease before long‑term treatment. - Consider tapering plans for patients who have been on therapy for more than a few weeks to avoid adrenal insufficiency. - Use with caution in pregnant or breastfeeding women, given limited safety data. - Screen for psychiatric disorders, as steroids may exacerbate mood or psychotic symptoms.

Hydrocortone can alter the pharmacokinetics or pharmacodynamics of several concomitant medicines; awareness of key interactions helps prevent therapeutic failure or toxicity.

Avoid: - Strong CYP3A4 inducers such as rifampin, phenytoin, or carbamazepine, which may reduce hydrocortisone plasma concentrations. - Systemic antifungal agents like ketoconazole that inhibit steroid metabolism and can increase exposure.

Use with caution: - Non‑steroidal anti‑inflammatory drugs (NSAIDs) because combined use raises the risk of gastrointestinal ulceration or bleeding. - Anticoagulants (e.g., warfarin) as glucocorticoids may enhance anticoagulant effects and affect INR. - Diabetic medications, since hydrocortisone can raise blood glucose and may require dose adjustments. - Vaccines, particularly live attenuated vaccines, because immunosuppression may diminish vaccine efficacy.